Wells Fargo initiated coverage on MiniMed with a new price target
$MMED
Medical/Dental Instruments
Health Care
Wells Fargo initiated coverage of MiniMed with a rating of Overweight and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/31/2026 | $25.00 | Buy | BTIG Research |
| 3/31/2026 | $20.00 | Buy | Deutsche Bank |
| 3/31/2026 | $27.00 | Buy | BofA Securities |
| 3/31/2026 | $16.00 | Neutral | Piper Sandler |
| 3/31/2026 | $21.00 | Outperform | Mizuho |
| 3/31/2026 | $19.00 | Overweight | Morgan Stanley |
| 3/31/2026 | $23.00 | Buy | Citigroup |
| 3/31/2026 | $20.00 | Outperform | Evercore ISI |
10-Q - MiniMed Group, Inc. (0002062583) (Filer)
8-K - MiniMed Group, Inc. (0002062583) (Filer)
8-K - MiniMed Group, Inc. (0002062583) (Filer)
NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. A news release will be issued at approximately 3:45 a.m. Pacific Daylight Time (PDT) and will be available at https://news.minimed.com. The news release will include summary financial information for the company's fourth quarter and full fiscal year 2026, which will end on Friday, April 24, 2026. MiniMed will host a webcast at 5:45 a.m. P
MiniMed Flex™ is about half the size of the previous generation MiniMed™ 780G system, and features the SmartGuard™ adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-timeNORTHRIDGE, Calif., March 18, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced U.S. Food and Drug Administration (FDA) clearance of MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump designed to fit seamlessly into everyday life. MiniMed Flex™ represents a major redesign of MiniMed's insulin pumps.About
NORTHRIDGE, Calif., March 9, 2026 /PRNewswire/ -- MiniMed Group, Inc. ((MiniMed, NASDAQ:MMED) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares began trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026 under the symbol "MMED." As of the closing of the IPO, Medtronic plc (Medtronic) owns approximately 90.03% of MiniMed common stock. Medtronic has previously stated that its preferred path to complete the separation is a split-off.Af
4 - MiniMed Group, Inc. (0002062583) (Issuer)
4 - MiniMed Group, Inc. (0002062583) (Issuer)
4 - MiniMed Group, Inc. (0002062583) (Issuer)
BTIG Research initiated coverage of MiniMed with a rating of Buy and set a new price target of $25.00
Deutsche Bank initiated coverage of MiniMed with a rating of Buy and set a new price target of $20.00
BofA Securities initiated coverage of MiniMed with a rating of Buy and set a new price target of $27.00